Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Citi
Harvard Business School
Accenture
Farmers Insurance
Queensland Health
Mallinckrodt
Medtronic

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,513,262

« Back to Dashboard

Which drugs does patent 8,513,262 protect, and when does it expire?

Patent 8,513,262 protects TYKERB and is included in one NDA.

This patent has seventy patent family members in forty-six countries.
Summary for Patent: 8,513,262
Title:Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
Abstract: A process for the preparation of a compound of formula (I) ##STR00001## comprising the steps: (a) reacting a compound of formula (II) ##STR00002## wherein L and L' are suitable leaving groups, with a compound of formula (III) UNH.sub.2 (III) to prepare a compound of formula (IV) ##STR00003## and subsequently (b) substituting the group R.sup.1 by replacement of the leaving group L'.
Inventor(s): Carter; Malcolm Clive (Ware, GB), Cockerill; George Stuart (Bedford, GB), Lackey; Karen Elizabeth (Hillsborough, NC)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:12/691,784
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form;

Drugs Protected by US Patent 8,513,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp TYKERB lapatinib ditosylate TABLET;ORAL 022059-001 Mar 13, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,513,262

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9800569Jan 12, 1998
99/00048Jan 08, 1999

Non-Orange Book US Patents Family Members for Patent 8,513,262

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,109,333 Heterocyclic compounds ➤ Try a Free Trial
8,912,205 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Try a Free Trial
9,199,973 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors ➤ Try a Free Trial
6,713,485 Heterocyclic compounds ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,513,262

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1446 ➤ Try a Free Trial
Argentina 015507 ➤ Try a Free Trial
Argentina 066982 ➤ Try a Free Trial
Austria 270670 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Medtronic
Dow
Healthtrust
Cipla
Fish and Richardson
US Army
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.